Literature DB >> 16675086

Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia.

Max Fink, Michael Alan Taylor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16675086     DOI： 10.1016/j.pnpbp.2006.03.029

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


× No keyword cloud information.
  7 in total

1.  Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses.

Authors:  Hadar Zaman; Roger Carl Gibson; Geoffrey Walcott
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

Review 2.  Catatonia in autism: implications across the life span.

Authors:  Angelina Kakooza-Mwesige; Lee E Wachtel; Dirk M Dhossche
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-04-21       Impact factor: 4.785

Review 3.  A clinical review of the treatment of catatonia.

Authors:  Pascal Sienaert; Dirk M Dhossche; Davy Vancampfort; Marc De Hert; Gábor Gazdag
Journal:  Front Psychiatry       Date:  2014-12-09       Impact factor: 4.157

4.  Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription.

Authors:  Thomas J Reilly; Sean Cross; David M Taylor; Richard Haslam; Sophie C Tomlin; Benjamin Gaastra
Journal:  SAGE Open Med Case Rep       Date:  2017-03-31

5.  Successful Treatment of Catatonia: A Case Report and Review of Treatment.

Authors:  Kevin Malone; Sall Saveen; Christopher M Stevens; Shawn McNeil
Journal:  Cureus       Date:  2022-06-25

Review 6.  Paralyzed by Fear?-A Case Report in the Context of Narrative Review on Catatonia.

Authors:  Karina Badura Brzoza; Patryk Główczyński; Michał Błachut
Journal:  Int J Environ Res Public Health       Date:  2022-08-16       Impact factor: 4.614

7.  Diagnostic and Therapeutic Challenges of Catatonia in an Adolescent With High Functioning Autism Spectrum Disorder: A Case Report.

Authors:  Annalisa Traverso; Caterina Ancora; Silvia Zanato; Alessia Raffagnato; Michela Gatta
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.